Entera Health Presents Possible New IBS Therapy

At the Experimental Biology 2013 meeting held in Boston April 20 to 24, Entera Health presented nonclinical studies demonstrating oral serum-derived bovine immunoglobulin/protein isolate (SBI) as a promising treatment for irritable bowel syndrome.
SBI promotes bone density and lean body mass growth, allowing for increased nutrient absorption.

Entera Health is a biotherapeutics company focused on developing treatments for gastroenterology, oncology and immune disorder conditions.

More Articles on Gastroenterology:
Innotex Receives Patent for Colon Cancer Suturing System
Heartland Regional Medical Center Opens Gastroenterology & Hepatology Clinic
Ferring Pharmaceuticals Launches Colon Cancer Awareness Campaign


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast